SilicoGene: Dutch Biotech Startup Participates in Slush 2024

December 1, 2024

SilicoGene, a biotech startup from the Netherlands, took part in Slush 2024 in Helsinki. The company presented its no-code platform, which streamlines MLOps processes in drug discovery. The platform ensures that AI models deliver reliable and ethical results in healthcare. SilicoGene was also part of the Dutch Delegation, highlighting its role in advancing health-tech AI and personalized medicine.

Simplifying Health-Tech AI

SilicoGene’s no-code platform supports health-tech teams at every stage of the MLOps lifecycle. It handles omics data analysis, deployment, and monitoring of AI models. The platform ensures safety and consistent quality in production.

By integrating computational biology with AI technology, SilicoGene addresses challenges in drug discovery. It focuses on solutions that are practical for healthcare applications.

At Slush 2024, SilicoGene:

  • Engaged with Investors and Industry Leaders: The team discussed how their platform reduces risks in drug discovery.
  • Presented Practical Solutions: They showcased the platform’s value in simplifying complex health-tech processes.
  • Built Connections: As part of the Dutch Delegation, they fostered partnerships with a global network of investors and researchers.

Addressing Challenges at the ‘Funding for Impact’ Event

SilicoGene also participated in the Funding for Impact event. Hosted by the Netherlands Ambassador in Helsinki, this session brought together founders and investors. Discussions focused on strategies to reduce risks in funding for startups and scale-ups.

At the roundtable, SilicoGene’s CEO Hossein Kamkar shared a key challenge: measuring impact with limited data. The event provided valuable insights on tackling this issue.

Key Takeaways:

  • Quantifying Impact: SilicoGene emphasized the importance of showing measurable results, even with limited data.
  • Proactively Addressing Risks: Transparency about potential challenges can build trust with investors.
  • Building Relationships: Sustained engagement with investors is vital for long-term growth.

“This event gave us a chance to connect with others facing similar challenges,” said Kamkar. “The insights we gained will help us navigate complex funding landscapes.”

Moving Forward

Following Slush 2024 and the Funding for Impact event, SilicoGene plans to:

  • Enhance Platform Features: The focus is on expanding capabilities for personalized medicine tailored to genetic profiles.
  • Strengthen Global Partnerships: Collaboration with biotech firms and research institutions remains a priority.
  • Refine Funding Strategies: Feedback from events will guide future approaches to funding and growth.

About SilicoGene

SilicoGene develops solutions to ensure AI models perform reliably and ethically in real-world healthcare. Its no-code platform supports the full MLOps lifecycle in drug discovery, from data analysis to deployment and monitoring. The company envisions a future where personalized medicine is accessible to all.